PD-1 blockade enhances the vaccination-induced immune response in glioma

Authors: Joseph P. Antonios,¹ Horacio Soto,¹ Richard G. Everson,¹ Joey Orpilla,¹ Diana Moughon,¹ Namjo Shin,¹ Shaina Sedighim,¹ William H. Yong,² Gang Li,³ Timothy F. Cloughesy,^4,5,6 Linda M. Liau,^1,4,5 and Robert M. Prins1,^4,5,7

Online: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4951098/

Issue: JCI Insight. 2016 Jul 7; 1(10): e87059.

Abstract

DC vaccination with autologous tumor lysate has demonstrated promising results for the treatment of glioblastoma (GBM) in preclinical and clinical studies. While the vaccine appears capable of inducing T cell infiltration into tumors, the effectiveness of active vaccination in progressively growing tumors is less profound. In parallel, a number of studies have identified negative costimulatory pathways, such as programmed death 1/programmed death ligand 1 (PD-1/PD-L1), as relevant mediators of the intratumoral immune responses. Clinical responses to PD-1 pathway inhibition, however, have also been varied. To evaluate the relevance to established glioma, the effects of PD-1 blockade following DC vaccination were tested in intracranial (i.c.) glioma tumor–bearing mice. Treatment with both DC vaccination and PD-1 mAb blockade resulted in long-term survival, while neither agent alone induced a survival benefit in animals with larger, established tumors. This survival benefit was completely dependent on CD8+ T cells. Additionally, DC vaccine plus PD-1 mAb blockade resulted in the upregulation of integrin homing and immunologic memory markers on tumor-infiltrating lymphocytes (TILs). In clinical samples, DC vaccination in GBM patients was associated with upregulation of PD-1 expression in vivo, while ex vivo blockade of PD-1 on freshly isolated TILs dramatically enhanced autologous tumor cell cytolysis. These findings strongly suggest that the PD-1/PD-L1 pathway plays an important role in the adaptive immune resistance of established GBM in response to antitumor active vaccination and provide us with a rationale for the clinical translation of this combination therapy.

AUTHOR AFFILIATIONS

1. Department of Neurosurgery,
2. Department of Pathology and Laboratory Medicine,
3. Department of Biostatistics,
4. Brain Research Institute,
5. Jonsson Comprehensive Cancer Center (JCCC),
6. Department of Neurology, and
7. Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, UCLA, Los Angeles, California, USA.